Scott Smith - Titan Pharmaceuticals Director
| TTNP Stock | USD 7.01 0.31 4.23% |
Director
Mr. Scott A. Smith serves as Director of the Company. He has served in various management capacities with Celgene Corporation since 2008, including as President, Inflammation and Immunology since August 2014. From 2003 to 2008, he served in various executive capacities with Biovail Pharmaceuticals, Inc. and prior thereto spent 16 years Pharmacia Upjohn Company since 2017.
| Age | 54 |
| Tenure | 7 years |
| Address | 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 244 4990 |
| Web | https://www.titanpharm.com |
Scott Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Smith against Titan Pharmaceuticals stock is an integral part of due diligence when investing in Titan Pharmaceuticals. Scott Smith insider activity provides valuable insight into whether Titan Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Titan Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Titan Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Acquisition by Scott Smith of 50000 shares of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 |
Titan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.749) % which means that it has lost $0.749 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3914) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/23/2024, Return On Tangible Assets is likely to drop to -0.72. In addition to that, Return On Capital Employed is likely to drop to -1.15. As of 04/23/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Total Current Liabilities is likely to drop slightly above 1.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| David Anstice | Alkermes Plc | 69 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Norah Barlow | Evotec SE ADR | N/A | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.75 |
Titan Pharmaceuticals Leadership Team
Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Rubin, Executive Chairman of the Board | ||
| Rajinder Kumar, Director | ||
| Brian Crowley, Senior Administration | ||
| Sunil Bhonsle, President, Secretary and Director | ||
| James McNab, Director | ||
| Federico Recli, Director | ||
| David MacFarlane, Independent Director | ||
| Joseph Akers, Director | ||
| Eurelio Cavalier, Independent Director | ||
| Marc MD, Ex Director | ||
| David Lazar, Principal Officer | ||
| Scott Smith, Director | ||
| Joe Schrei, Executive Operations | ||
| Katherine BeebeDeVarney, COO President | ||
| Ley Smith, Independent Director | ||
| Dane Hallberg, Executive Vice President and Chief Commercial Officer | ||
| Jennifer Kiernan, Executive Coordinator | ||
| Victor Bauer, Independent Director | ||
| Seghi Recli, Lead Director | ||
| Mike Fritz, National Director |
Titan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (39.55) % | ||||
| Current Valuation | 497.74 K | ||||
| Shares Outstanding | 914.23 K | ||||
| Shares Owned By Insiders | 45.46 % | ||||
| Shares Owned By Institutions | 5.51 % | ||||
| Number Of Shares Shorted | 3.91 K | ||||
| Price To Earning | (3.60) X | ||||
| Price To Book | 1.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Titan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Titan Pharmaceuticals' short interest history, or implied volatility extrapolated from Titan Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.41) | Revenue Per Share 0.245 | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.39) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.